Sheharyar Sajjad Baig

Sheharyar Sajjad Baig

Auto-generated profile, based on publicly available information

Sheharyar Sajjad Baig

Sheffield Institute for Translational Neuroscience, The University of Sheffield, Sheffield, UK

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 July 2016 in Neurodegenerative Disease Management
Verified
Journal Article
Closed access
SBSheharyar Sajjad Baig
Sheharyar Sajjad Baig
MSMark Strong
Mark Strong
OQOliver Wj Quarrell
Oliver Wj Quarrell
The ascertained prevalence of Huntington's disease (HD) increased significantly following the provision of diagnostic testing. A systematic review was conducted to estimate the prevalence of HD in the post-diagnostic testing era. Twenty-two studies with original data pertaining to the prevalence of HD (1993–2015) were included and analyzed. A global meta-analysis was not performed due to heterogeneity in study methods and geographical variation. The prevalence of HD is significantly lower in Asian populations compared with western Europe, North America and Australia. The global variation in HD prevalence is partly explained by the average CAG repeat lengths and frequency of different HTT gene haplotypes in the general population. Understanding the prevalence of HD has significant implications for healthcare resource planning.

11 May 2016 in European Journal of Human Genetics
Verified
Journal Article
Open access
PDF file
UCUK Huntington’s Disease Prediction Consortium
UK Huntington’s Disease Prediction Consortium
SBSheharyar S Baig
Sheharyar S Baig
MSMark Strong
Mark Strong
ERElisabeth Rosser
Elisabeth Rosser
NTNicola V Taverner
Nicola V Taverner
OQOliver W Quarrell
Oliver W Quarrell
Huntington’s disease (HD) is a progressive neurodegenerative condition. At-risk individuals have accessed predictive testing via direct mutation testing since 1993. The UK Huntington’s Prediction Consortium has collected anonymised data on UK predictive tests, annually, from 1993 to 2014: 9407 predictive tests were performed across 23 UK centres. Where gender was recorded, 4077 participants were male (44.3%) and 5122 were female (55.7%). The median age of participants was 37 years. The most common reason for predictive testing was to reduce uncertainty (70.5%). Of the 8441 predictive tests on individuals at 50% prior risk, 4629 (54.8%) were reported as mutation negative and 3790 (44.9%) were mutation positive, with 22 (0.3%) in the database being uninterpretable. Using a prevalence figure of 12.3 × 10−5, the cumulative uptake of predictive testing in the 50% at-risk UK population from 1994 to 2014 was estimated at 17.4% (95% CI: 16.9–18.0%). We present the largest study conducted on predictive testing in HD. Our findings indicate that the vast majority of individuals at risk of HD (>80%) have not undergone predictive testing. Future therapies in HD will likely target presymptomatic individuals; therefore, identifying the at-risk population whose gene status is unknown is of significant public health value.

1 July 2021 in Stroke
Verified
Journal Article
Closed access
PDF file
AAAli NASSER ALI
Ali NASSER ALI
DTDina Tabassum
Dina Tabassum
SBSheharyar S. Baig
Sheharyar S. Baig
BMBethany Moyle
Bethany Moyle
JRJessica Redgrave
Jessica Redgrave
AMArshad Majid
Arshad Majid
Exercise interventions have been shown to help physical fitness, walking, and balance after stroke, but data are lacking on whether such interventions lead to improvements in health-related quality of life (HRQoL). In this systematic review and meta-analysis, 30 randomized controlled trials (n=1836 patients) were found from PubMed, OVID MEDLINE, Web of Science, CINAHL, SCOPUS, The Cochrane Library, and TRIP databases when searched from 1966 to February 2020 that examine the effects of exercise interventions on HRQoL after stroke or transient ischemic attack. Exercise interventions resulted in small to moderate beneficial effects on HRQoL at intervention end (standardized mean difference, −0.23 [95% CI, −0.40 to −0.07]) that appeared to diminish at longer-term follow-up (standardized mean difference, −0.11 [95% CI, −0.26 to 0.04]). Exercise was associated with moderate improvements in physical health (standardized mean difference, −0.33 [95% CI, −0.61 to −0.04]) and mental health (standardized mean difference, −0.29 [95% CI, −0.49 to −0.09]) domains of HRQoL while effects on social or cognitive composites showed little difference. Interventions that were initiated within 6 months, lasted at least 12 weeks in duration, involved at least 150 minutes per week, and included resistance training appeared most effective. Exercise can lead to moderate beneficial effects on HRQoL and should be considered an integral part of stroke rehabilitation.

1 December 2019 in Journal of Stroke and Cerebrovascular Diseases
Verified
Journal Article
Closed access
SBSheharyar Sajjad Baig
Sheharyar Sajjad Baig
KFKonstantinos Falidas
Konstantinos Falidas
PLPeter J. Laud
Peter J. Laud
NSNicola Snowdon
Nicola Snowdon
MFMuhammad Umar Farooq
Muhammad Umar Farooq
JRJessica N. Redgrave
Jessica N. Redgrave

27 November 2023 in Current Neurology and Neuroscience Reports
Verified
Journal Article
Open access
PDF file
SASasan Andalib
Sasan Andalib
Afshin A. DivaniAfshin A. Divani
Afshin A. Divani
CACenk Ayata
Cenk Ayata
SBSheharyar Baig
Sheharyar Baig
EAEthem Murat Arsava
Ethem Murat Arsava
MNMario Di Napoli
Mario Di Napoli
Purpose of Review Vagus nerve stimulation (VNS) has emerged as a potential therapeutic approach for neurological and psychiatric disorders. In recent years, there has been increasing interest in VNS for treating ischemic stroke. This review discusses the evidence supporting VNS as a treatment option for ischemic stroke and elucidates its underlying mechanisms. Recent Findings Preclinical studies investigating VNS in stroke models have shown reduced infarct volumes and improved neurological deficits. Additionally, VNS has been found to reduce reperfusion injury. VNS may promote neuroprotection by reducing inflammation, enhancing cerebral blood flow, and modulating the release of neurotransmitters. Additionally, VNS may stimulate neuroplasticity, thereby facilitating post-stroke recovery. Summary The Food and Drug Administration has approved invasive VNS (iVNS) combined with rehabilitation for ischemic stroke patients with moderate to severe upper limb deficits. However, iVNS is not feasible in acute stroke due to its time-sensitive nature. Non-invasive VNS (nVNS) may be an alternative approach for treating ischemic stroke. While the evidence from preclinical studies and clinical trials of nVNS is promising, the mechanisms through which VNS exerts its beneficial effects on ischemic stroke are still being elucidated. Therefore, further research is needed to better understand the efficacy and underlying mechanisms of nVNS in ischemic stroke. Moreover, large-scale randomized clinical trials are necessary to determine the optimal nVNS protocols, assess its long-term effects on stroke recovery and outcomes, and identify the potential benefits of combining nVNS with other rehabilitation strategies.

1 October 2023 in Stroke
Verified
Journal Article
Closed access
SBSheharyar S. Baig
Sheharyar S. Baig
MKMarharyta Kamarova
Marharyta Kamarova
SBSimon Bell
Simon Bell
AAAli NASSER ALI
Ali NASSER ALI
LSLi Su
Li Su
AMArshad Majid
Arshad Majid
Ischemic stroke is a leading cause of disability and there is a paucity of therapeutic strategies that promote functional recovery after stroke. Transcutaneous vagus nerve stimulation (tVNS) has shown promising evidence as a tool to reduce infarct size in animal models of hyperacute stroke. In chronic stroke, tVNS paired with limb movements has been shown to enhance neurological recovery. In this review, we summarize the current evidence for tVNS in preclinical models and clinical trials in humans. We highlight the mechanistic pathways involved in the beneficial effects of tVNS. We critically evaluate the current gaps in knowledge and recommend the key areas of research required to translate tVNS into clinical practice in acute and chronic stroke.